ReviewJournal, genetic engineering & biotechnology2026
Advancements of mRNA-lipid nanoparticle links to gene editing and immune responses.
Review in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid-formulated liposomes have been utilized for the transport of various biological substances, including mRNA molecules. Basically, large lipids play a crucial role in the structure and function of cell membranes. In protein synthesis, mRNA plays a crucial role in expressing the proteins. In this context, this natural process enables gene editing, protein replacement therapy, cancer immunotherapy, cellular reprogramming, and vaccinations. A range of biomaterials is utilized for mRNA transport, including polymers, lipid-based nanoparticles, and protein-mRNA complexes. Thus, the review aims to analyse the mRNA-lipid nanoparticles assigned with gene editing and the mechanisms to enhance immune responses to infectious diseases. A nonviral lipid nanoparticle approach for CRISPR-Cas9 gene editing has achieved up to 80% gene editing in vivo and 98% in vitro across various cancer cell types. MEVPCS-mRNA LNPs, as a preventative HIV vaccine, elicit comparable and highly specific immune responses via CD8+ T cells. Th1-type CD4+ T cell responses are notable in mice immunized with LNP-mRNA, indicating a substantial impact on Mycobacterium tuberculosis. Variations in pH, ionic strength, and freezing rate are essential for enhancing the lyophilization of mRNA lipid nanoparticles. The polydispersity index has risen from 0.1 to 0.3, and the LNP particle size in the Vibrating Membrane Nebulizer has increased from an average of 85 nm to 300 nm, suggesting notable structural degradation due to elevated shear stresses. The Laminar Fluid Ejection Device enhanced the stability of lipid nanoparticles. This enhances the immune response and effectively manages harmful microbes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.